
Former investment banker Kenichi Nogami (’17) embraced the Business Creation Option at UCLA Anderson because he wanted to bring vital medical technology to market. He says he chose Anderson because of its location in a region of cutting-edge medical technology and a culture of shared success that sets it apart from other b-schools.
Q: Tell us about your startup, Metcela.
Metcela is a pioneer biotechnology company founded in Japan in March 2016 that aims to be the first to commercialize biological products that heal damaged heart muscle in order to treat heart diseases. The product can save patients’ lives by preventing risky and expensive heart transplants, which can cost up to $787,000.
I co-founded the company with my partner, Takahiro Iwamiya, an experienced stem cell researcher in Japan, while getting support from UCLA Anderson classmates.
Q: What inspired you, and how did your education and experience prepare you to launch your own venture?
Before coming to UCLA Anderson, I was an investment banker at Morgan Stanley in Japan and I executed financing and M&A deals for major Japanese companies. But I had entrepreneurial aspirations in my mind since college. In January 2014, while I was still at Morgan Stanley, I met Takahiro and, after several meetings, we decided to work together to launch a business from his technology. However, as a former investment banker, I had no clue about the steps of launching the business and what strategy we should take. I decided to apply to business schools to learn more about entrepreneurship while Takahiro worked on R&D and prototyping for a couple of years. Anderson resources really helped me in creating convincing business plans and presenting them to investors. Capitalizing on all the learnings here, we could convince one key venture capitalist in Japan and actually launch the company.
Q: Describe disruption and innovation in the medical space. What differences have you noticed between Asia and the U.S.?
The Japanese government is provding a lot of grants to researchers and companies in the field of stem cell research. In addition, the government also enforced a new law to reduce difficulty of stem cell clinical trials and promote commercializing stem cell treatment. Taking advantage of this support, Metcela received a grant from the government in May and we located our first lab in the stem cell-focused research center developed under a prefectural project, starting June 1.